Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years, large Phase III trials showed improvements in survival and outcomes and led to the approval of a CYP17 inhibitor (abiraterone), an androgen receptor antagonist (enzalutamide), the taxane cabazitaxel, an α-emitter (radium-223), the bone resorption-targeting drug denosumab and an immunotherapy (sipuleucel-T). This article describes the molecular mechanisms underlying castration resistance, discusses recent and ongoing trials and offers some insights into identifying the best sequence of new drugs. KEYWORDS: bone-targeting agents; castration-resistant prostate cancer; chemotherapy; endocrine therapy; immunotherapy

Metastatic castration-resistant prostate cancer: Time for innovation

SCAGLIOTTI, Giorgio Vittorio
;
VIGNANI, FRANCESCA
2015-01-01

Abstract

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years, large Phase III trials showed improvements in survival and outcomes and led to the approval of a CYP17 inhibitor (abiraterone), an androgen receptor antagonist (enzalutamide), the taxane cabazitaxel, an α-emitter (radium-223), the bone resorption-targeting drug denosumab and an immunotherapy (sipuleucel-T). This article describes the molecular mechanisms underlying castration resistance, discusses recent and ongoing trials and offers some insights into identifying the best sequence of new drugs. KEYWORDS: bone-targeting agents; castration-resistant prostate cancer; chemotherapy; endocrine therapy; immunotherapy
2015
11
1
91
106
http://www.futuremedicine.com/loi/fon
Bone-targeting agents; castration-resistant prostate cancer; chemotherapy; endocrine therapy; immunotherapy; Oncology; Cancer Research
Tucci, Marcello; Scagliotti, Giorgio Vittorio; Vignani, Francesca
File in questo prodotto:
File Dimensione Formato  
metastatic castration.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.85 MB
Formato Adobe PDF
1.85 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1522511
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 31
social impact